The CE mark has been granted to DiaCarta for ColoScape, a colorectal cancer (CRC) mutation detection kit. Approved for use in Europe, ColoScape uses DiaCarta’s QClamp technology to identify 20 proprietary, clinically validated CRC mutation markers from four oncogenes. QClamp is a patented xeno nucleic acid-based clamping technology that uses quantitative polymerase chain reaction (PCR). In a preliminary study performed by DiaCarta and its collaborators, ColoScape correctly identified > 95% of stage 1–4 CRC cases. DiaCarta also examined ColoScape’s performance in precancer screening and found that the test demonstrated a sensitivity of 62%, compared with the 42.4% sensitivity of the noninvasive CRC test Cologuard. ColoScape runs in less than 2.5 hours with a minimum of 20 ng of DNA from formalin-fixed, paraffin-embedded tumor, plasma, or stool samples. It also operates on a variety of common real-time PCR platforms using kits that leverage proprietary multiplexed TaqMan chemistry.